If you want to know Bionaturis’ latest news, here you are our May Newsletter

Imagen Bionaturis Newsletter

IN THIS ISSUE

  • Bionaturis fulfilled its 3 million € increase of capital with oversubscription
  • Bionaturis 2013 annual report
  • “Educate yourself and help introduce collective learning processes”

Let’s get to know…

Elena de la Torre Madrid, 34 years old, born in Madrid. PhD in Biochemistry at Universidad Autónoma and Master in Biotechnology Management.

 

Elena de la Torre

  • -When you were a child, what did you want to be as an adult?
  • A doctor.
  • -What do you like the most about your job?
  • Being part of something that has effect in society, knowing that we can improve something.
  • -What are your future challenges?
  • Keep on training in order to overcome my weeknesses.
  • -Your favourite dish
  • Paella (cooked by my father).
  • -A place
  • Paris.
  • -A film
  • ‘The Silence of the Lambs’, by Jonathan Demme.
  • -A historical figure
  • The Apostle Paul.
  • -A book
  • ‘The Lord of the Rings’, by Tolkien.
  • -A song
  • ‘Nessun Dorma’, from the opera ‘Turandot’.
  • -What do you usually do in your free time?
  • Reading, cooking, walking, watching series…
  • -A proposal to get rid of the crisis
  • Reducing unnecessary expenses of public administrations: advisors, official cars and trips, controlling politicians´incomes, etc.., while investing more and more in R&D instead.
  • -How do you imagine the world in 20 years?
  • I can imagine it worse and worse. Social demands are making us more independents, selfish and leisure-seekers. I´ll do my best to change it at least as far as I could.
  Elena has been working as Project Manager at Bionaturis since April 2014.

Bionaturis fulfilled its 3 million € increase of capital with oversubscription

Bionaturis (BNT-MAB), an international reference company developing biological vaccines, has managed to raise 3.088.687 €, 100% of the recent increase of capital offer. It´s noteworthy that there has been an oversubscription of 76% of the total new issued shares. As a result, 441.241 new shares of a nominal value of 0.05 € each, plus an issue premium of 6.95 € have been subscribed[...] Read more

Bionaturis 2013 annual report

Bionaturis (BNT-MAB), an international reference company developing biological drugs, has released the 2013 Annual Report.Victor Infante, Bionaturis’ CEO, has commented about the results: “The important point here is that our performance supports our strategy. Now the focus is on the internationalization process and to achieve the milestones needed to move forward our BNT programs to the market. We are on the right track. We keep estimations to increase our revenues around 400% this year”.[...] Read more

 

“Educate yourself and help introduce collective learning processes”

The eager of a continuous training not only for managers but also for employees is the key of the third point of the Decalogue about the executive role written by Juan José Almagro, president of Bionaturis. Almagro, recently named deputy President of UNICEF Spain, is a lawyer, PhD in Work Sciences, columnist and writer.
[...] Read more

 

INVESTOR INFO

Relevant Info: increasing and reducing of social capitalNotice: Starting of quotation of 441.241 new issued shares belonged to the capital increase April 2014

Financial information: Bionaturis 2013 annual report

Hi, this newsletter contains information about my website. For any question, please contact to info@bionaturis.com
Imagen Boletín Bionaturis Imagen Twitter Bionaturis Imagen Linked In Bionaturis Imagen Flickr Bionaturis Imagen Youtube Bionaturis Imagen Blog Bionaturis

Este e-mail ha sido enviado por *|EMAIL|*¿Por qué me sale esto?    No quiero seguir recibiendo este newsletter    Actualizar las preferencias de suscripción

*|LIST:ADDRESSLINE|*

*|REWARDS|*